NON-EXUDATIVE (DRY) AGE-RELATED MACULAR DEGENERATION (DAMD)

Clinical trials for NON-EXUDATIVE (DRY) AGE-RELATED MACULAR DEGENERATION (DAMD) explained in plain language.

Never miss a new study

Get alerted when new NON-EXUDATIVE (DRY) AGE-RELATED MACULAR DEGENERATION (DAMD) trials appear

Sign up with your email to follow new studies for NON-EXUDATIVE (DRY) AGE-RELATED MACULAR DEGENERATION (DAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New pill aims to halt leading cause of blindness in seniors

Disease control Not yet recruiting

This study is testing if a daily oral medication called EG-301, when added to standard eye health supplements, can slow the progression of vision loss in people with a specific form of dry age-related macular degeneration (AMD). It will involve 90 participants, aged 50-75, who ha…

Matched conditions: NON-EXUDATIVE (DRY) AGE-RELATED MACULAR DEGENERATION (DAMD)

Phase: PHASE2 • Sponsor: Evergreen Therapeutics, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:32 UTC

NON-EXUDATIVE (DRY) AGE-RELATED MACULAR DEGENERATION (DAMD)

Get alerted when new NON-EXUDATIVE (DRY) AGE-RELATED MACULAR DEGENERATION (DAMD) trials appear

New pill aims to halt leading cause of blindness in seniors